Medical technology giant Medtronic will purchase ... of our innovative pipeline products, and will expand access to our therapies and offerings to the sizeable heart failure population." ...

About a year ago, renal denervation procedures won a huge victory after finally being greenlit by FDA. Now two of the frontrunners in the space have received reimbursement.

The U.S. Food and Drug Administration (FDA) has greenlighted Medtronic’s (NYSE:MDT) PulseSelect Pulsed Field Ablation (PFA) System targeted at a heart rhythm ... roll out the product in early ...

Medtronic plc (NYSE ... Spine and Structural Heart products. The company provided in-line guidance for the fiscal full-year 2025, with EPS expected between $5.42 to $5.50 versus $5.44 consensus ...

which is part of the Medtronic Cardiovascular Portfolio. "The potential of Affera is limitless. We will continue to fulfill our commitment to innovation, including new indications, to advance ...

The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. Here’s what the results mean for the ...

This half course provides an introduction to product management, focused primarily on improving and scaling existing products at technology companies. It is designed for three types of students: Those ...

Medtronic has announced US Food and Drug Administration (FDA) approval to conduct an early feasibility study using the Affera Mapping and Ablation System for sustained VT, a serious heart condition.

First-of-its-kind, all-in-one HD-mapping and dual energy (pulsed field and radiofrequency) ablation catheter Highly anticipated by electrophysiologists for its innovation and demonstrated safety ...